Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro: Quantitative and qualitative effects of CD4+ T cells

Vaccine

Volumn 26, Issue 32, 2008, Pages 3987-3997

  Kim, Eun Kyung ^a   Cho, Hyun Il ^a   Yoon, Sung Hee ^a   Park, Min Ji ^a   Sohn, Hyun Jung ^a   Kim, Hyung Jin ^b   Oh, Seong Taek ^b   Kim, Tai Gyu ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Cytotoxic T cells; Survivin; T helper 1 cells

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN PP65; RECOMBINANT PROTEIN; SURVIVIN; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ARTICLE; CD25+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VIRAL PROTEINS;

EID: 47149099327     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.036     Document Type: Article

References (39)

1. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of the National Academy of Sciences of the United States of America 99 December 10 (25) (2002) 16168-16173
2. Powell Jr. D.J., Dudley M.E., Hogan K.A., Wunderlich J.R., and Rosenberg S.A. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Journal of Immunology 177 November 1 (9) (2006) 6527-6539
3. Cho H.I., Kim H.J., Oh S.T., and Kim T.G. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 22 December 12 (2) (2003) 224-236
4. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., and Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 February 20 (6925) (2003) 852-856
5. Shedlock D.J., and Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (New York, NY) 300 April 11 (5617) (2003) 337-339
6. Bourgeois C., Veiga-Fernandes H., Joret A.M., Rocha B., and Tanchot C. CD8 lethargy in the absence of CD4 help. European Journal of Immunology 32 August (8) (2002) 2199-2207
7. Sun J.C., and Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (New York, NY) 300 April 11 (5617) (2003) 339-342
8. Stuhler G., and Schlossman S.F. Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets. Proceedings of the National Academy of Sciences of the United States of America 94 January 21 (2) (1997) 622-627
9. Ostankovitch M., Le Gal F.A., Connan F., Chassin D., Choppin J., and Guillet J.G. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro. International Journal of Cancer 72 September 17 (6) (1997) 987-994
10. Eiz-Vesper B., Horn P.A., Daubert C., Khattab B., and Blasczyk R. Tetanus toxoid provides efficient T-cell help for the induction of HA-1(H) cytotoxic T cells. Transfusion 46 July (7) (2006) 1210-1220
11. Cerny A., Fowler P., Brothers M.A., Houghton M., Schlicht H.J., and Chisari F.V. Induction in vitro of a primary human antiviral cytotoxic T cell response. European Journal of Immunology 25 February (2) (1995) 627-630
12. Pardoll D.M., and Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Current Opinion in Immunology 10 October (5) (1998) 588-594
13. Chakraborty N.G., Chattopadhyay S., Mehrotra S., Chhabra A., and Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Human Immunology 65 August (8) (2004) 794-802
14. Steitz J., Bruck J., Lenz J., Knop J., and Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Research 61 December 15 (24) (2001) 8643-8646
15. Eloit M., Gilardi-Hebenstreit P., Toma B., and Perricaudet M. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. The Journal of General Virology 71 October (Pt 10) (1990) 2425-2431
16. Cook E.B., Stahl J.L., Lowe L., Chen R., Morgan E., Wilson J., et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. Journal of Immunological Methods 254 August 1 (1-2) (2001) 109-118
17. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96 September 1 (5) (2000) 1921-1925
18. Chakravarti A., Noll E., Black P.M., Finkelstein D.F., Finkelstein D.M., Dyson N.J., et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Journal of Clinical Oncology 20 February 15 (4) (2002) 1063-1068
19. Grossman D., McNiff J.M., Li F., and Altieri D.C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. The Journal of Investigative Dermatology 113 December (6) (1999) 1076-1081
20. Oh S.T., Kim C.H., Park M.Y., Won E.H., Sohn H.J., Cho H.I., et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 24 April 5 (15) (2006) 2860-2868
21. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine 3 August (8) (1997) 917-921
22. Cottrez F., and Groux H. Specialization in tolerance: innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells. Transplantation 77 January 15 (Suppl 1) (2004) S12-S15
23. Olive M., Eisenlohr L., Flomenberg N., Hsu S., and Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Human Gene Therapy 13 July 1 (10) (2002) 1167-1178
24. Carlsson B., Hou M., Giandomenico V., Nilsson B., Totterman T.H., and Essand M. Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein. The Journal of Infectious Diseases 192 December 1 (11) (2005) 1912-1920
25. Torre-Amione G., Beauchamp R.D., Koeppen H., Park B.H., Schreiber H., Moses H.L., et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proceedings of the National Academy of Sciences of the United States of America 87 February (4) (1990) 1486-1490
26. Karlsson H., Brewin J., Kinnon C., Veys P., and Amrolia P.J. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. Journal of Immunotherapy (1997) 30 July-August (5) (2007) 544-556
27. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 October 14 (6754) (1999) 708-712
28. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 September 1 (5) (1998) 1549-1555
29. Mackey M.F., Barth Jr. R.J., and Noelle R.J. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. Journal of Leukocyte Biology 63 April (4) (1998) 418-428
30. Andersen M.H., Pedersen L.O., Capeller B., Brocker E.B., Becker J.C., and thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Research 61 August 15 (16) (2001) 5964-5968
31. Andersen M.H., Pedersen L.O., Becker J.C., and Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Research 61 February 1 (3) (2001) 869-872
32. Casati C., Dalerba P., Rivoltini L., Gallino G., Deho P., Rini F., et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Research 63 August 1 (15) (2003) 4507-4515
33. Rohayem J., Diestelkoetter P., Weigle B., Oehmichen A., Schmitz M., Mehlhorn J., et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Research 60 April 1 (7) (2000) 1815-1817
34. Pisarev V., Yu B., Salup R., Sherman S., Altieri D.C., and Gabrilovich D.I. Full-length dominant-negative survivin for cancer immunotherapy. Clinical Cancer Research 9 December 15 (17) (2003) 6523-6533
35. Schmitz M., Diestelkoetter P., Weigle B., Schmachtenberg F., Stevanovic S., Ockert D., et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Research 60 September 1 (17) (2000) 4845-4849
36. Zeis M., Siegel S., Wagner A., Schmitz M., Marget M., Kuhl-Burmeister R., et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. Journal of Immunology 170 June 1 (11) (2003) 5391-5397
37. Park S.D., Kim C.H., Kim C.K., Park J.A., Sohn H.J., Hong Y.K., et al. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 25 April 30 (17) (2007) 3485-3491
38. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Reviews 4 December (12) (2004) 941-952
39. Griffiths R.W., Elkord E., Gilham D.E., Ramani V., Clarke N., Stern P.L., et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunology Immunotherapy 56 November (11) (2007) 1743-1753